SOCS3抗体;SOCS3 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using SOCS3 mouse mAb against Hela cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using SOCS3 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using SOCS3 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using SOCS3 mouse mAb with DAB staining.    

  
  

SOCS3 (Suppressor of Cytokine Signaling 3) antibodies are essential tools for studying the regulation of cytokine signaling pathways in cellular and molecular research. SOCS3 is a member of the SOCS family, which negatively regulates the JAK-STAT signaling cascade by binding to cytokine receptors or JAK kinases, targeting them for proteasomal degradation. It plays a critical role in modulating immune responses, inflammation, and cancer progression. SOCS3 antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to detect SOCS3 protein expression levels, localization, and interactions in various biological samples.

These antibodies are typically raised against specific epitopes of human or mouse SOCS3. with monoclonal and polyclonal variants available. Monoclonal antibodies offer high specificity, while polyclonal antibodies may provide broader detection across species. Researchers utilize SOCS3 antibodies to explore its involvement in diseases such as cancer (e.g., tumor suppression or oncogenic roles), autoimmune disorders, and metabolic conditions like obesity and insulin resistance. Challenges in working with SOCS3 antibodies include low endogenous protein expression in certain tissues, potential cross-reactivity with other SOCS family members (e.g., SOCS1 or SOCS2), and variability due to post-translational modifications. Proper validation using knockout controls or siRNA-based knockdown is critical to ensure specificity. Commercial SOCS3 antibodies often cite applications in both normal and pathological contexts, emphasizing their utility in uncovering mechanisms of cytokine signaling dysregulation.